Sotera Health Company — Form 8-K Summary
Reporting date: May 30, 2024. The filing reports a material debt refinancing, issuance of senior secured notes, termination of the prior term-loan agreement, and related changes to creditor and shareholder rights.
Business Context and Reporting Period
Sotera Health Company, through Sotera Health Holdings, LLC and related subsidiaries, refinanced its outstanding term loans that were scheduled to mature in December 2026. The transaction did not provide operating results for a quarterly or annual reporting period.
Key Financial and Capital Structure Details
- Refinancing term loans: $1.509 billion aggregate principal amount, maturing May 30, 2031.
- Term-loan pricing: ABR plus 2.25% for ABR loans, daily simple SOFR plus 3.25% for RFR loans, and Term SOFR plus 3.25% for Term Benchmark loans, each subject to a 0% floor.
- Pricing step-down: The applicable margin may decrease by 0.25% if the Senior Secured Leverage Ratio is 3.30:1.00 or lower.
- Term-loan amortization: 1.00% per year.
- New senior secured notes: $750 million aggregate principal amount, bearing interest at 7.375% annually and maturing June 1, 2031.
- Interest payments: The notes pay interest semiannually on June 1 and December 1, beginning December 1, 2024.
- Collateral and guarantees: The notes are jointly and severally guaranteed by the Company and Guarantors and secured on a first-lien, pari passu basis with the Credit Agreement by substantially all assets securing that facility, subject to exclusions and permitted liens.
- Use of proceeds: Refinancing term-loan proceeds, note proceeds, and cash on hand were used to repay all outstanding loans under the 2023 Credit Agreement.
- Debt, liquidity, cash flow, revenue, profit, and margins: The filing does not provide operating performance, cash-flow, liquidity-balance, or margin metrics. Cash on the balance sheet was used as part of the refinancing, but the remaining cash balance is not disclosed.
Material Changes Versus the Prior Comparable Position
- The 2023 Credit Agreement was repaid in full and terminated on May 30, 2024.
- The Company replaced the prior term loans with $1.509 billion of refinancing term loans and $750 million of senior secured notes, extending stated maturities to 2031.
- The refinancing introduced fixed-rate note obligations at 7.375% and new debt covenants that may restrict dividends, additional indebtedness, liens, investments, asset sales, affiliate transactions, and certain mergers or consolidations.
- The new notes and related guarantees rank equally with other unsubordinated obligations, are effectively senior to unsecured debt to the extent of collateral value, and are structurally subordinated to liabilities of non-guarantor subsidiaries.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no operating guidance or earnings outlook.
- The refinancing increases the Company’s long-term debt obligations and interest expense exposure; the filing does not quantify the change in annual interest expense.
- The term loans include a 1.00% soft-call premium for certain repricing transactions during the six months following the amendment.
- The notes may generally be redeemed beginning June 1, 2027, subject to specified prices and conditions. Prior to that date, certain make-whole, equity-offering, and limited annual redemption provisions apply.
- Upon specified changes of control combined with certain rating events, noteholders may require repurchase at 101% of principal plus accrued interest.
- The notes were issued in a private offering under Rule 144A and Regulation S and are not registered under the Securities Act or state securities laws.
- The notes’ covenants may limit SHH’s ability to pay dividends, potentially affecting dividends to Sotera Health common-stock holders. The covenants may be suspended if the notes receive an investment-grade rating.
- The complete Credit Agreement amendment, Indenture, Notes, and Security Agreement were stated to be filed with the Company’s Form 10-Q for the quarter ended June 30, 2024.
Important Facts for Investors to Verify
- Final executed debt documents, including all definitions, baskets, financial covenants, collateral provisions, and events of default.
- The refinancing’s effect on total debt, weighted-average interest rate, annual cash interest expense, and required amortization.
- The Company’s post-refinancing cash balance and available revolving-credit capacity.
- Current and projected Senior Secured Leverage Ratio compliance and the potential eligibility for the 0.25% term-loan pricing step-down.
- Any restrictions on dividends, equity distributions, asset sales, additional debt, or liens under the new financing documents.
- Whether the refinancing generated fees, premiums, unamortized debt issuance costs, or other accounting charges.
- The Company’s subsequent Form 10-Q disclosures regarding the refinancing and operating results for the quarter ended June 30, 2024.